- Home
- MCY vs MRUS Comparison
MCY vs MRUS Comparison
Compare MCY & MRUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MCY
- MRUS
- Stock Information
- Founded
- MCY 1961
- MRUS 2003
- Country
- MCY United States
- MRUS Netherlands
- Employees
- MCY N/A
- MRUS N/A
- Industry
- MCY Property-Casualty Insurers
- MRUS Biotechnology: Pharmaceutical Preparations
- Sector
- MCY Finance
- MRUS Health Care
- Exchange
- MCY Nasdaq
- MRUS Nasdaq
- Market Cap
- MCY 4.3B
- MRUS 5.1B
- IPO Year
- MCY N/A
- MRUS 2016
- Fundamental
- Price
- MCY $86.14
- MRUS $94.27
- Analyst Decision
- MCY Strong Buy
- MRUS Buy
- Analyst Count
- MCY 1
- MRUS 18
- Target Price
- MCY $100.00
- MRUS $93.72
- AVG Volume (30 Days)
- MCY 241.4K
- MRUS 4.0M
- Earning Date
- MCY 10-28-2025
- MRUS 10-30-2025
- Dividend Yield
- MCY 1.46%
- MRUS N/A
- EPS Growth
- MCY 22.11
- MRUS N/A
- EPS
- MCY 7.04
- MRUS N/A
- Revenue
- MCY $5,768,316,000.00
- MRUS $56,228,000.00
- Revenue This Year
- MCY $7.13
- MRUS $47.25
- Revenue Next Year
- MCY $7.60
- MRUS N/A
- P/E Ratio
- MCY $12.35
- MRUS N/A
- Revenue Growth
- MCY 14.93
- MRUS 59.77
- 52 Week Low
- MCY $44.19
- MRUS $33.19
- 52 Week High
- MCY $87.50
- MRUS $94.56
- Technical
- Relative Strength Index (RSI)
- MCY 72.48
- MRUS 86.21
- Support Level
- MCY $81.52
- MRUS $66.13
- Resistance Level
- MCY $85.96
- MRUS $94.39
- Average True Range (ATR)
- MCY 1.90
- MRUS 1.36
- MACD
- MCY 0.33
- MRUS 2.59
- Stochastic Oscillator
- MCY 85.73
- MRUS 98.98
About MCY Mercury General Corporation
Mercury General Corp is an insurance holding company. It is engaged in writing personal automobile insurance and provides related property and casualty insurance products. The Company offers the following types of automobile coverage: collision, property damage, bodily injury ("BI"), comprehensive, personal injury protection ("PIP"), underinsured and uninsured motorist, and other hazards. The Company offers the following types of homeowners coverage: dwelling, liability, personal property, and other coverages.
About MRUS Merus N.V.
Merus NV is a clinical-stage immuno-oncology company. It develops bispecific antibody therapeutics. The company is developing full-length human multispecific antibody therapeutics, referred to as Biclonics. Merus has only one reportable segment comprising the discovery and development of bispecific therapeutics. Some of its products in the pipeline include MCLA-128; MCLA-117; MCLA-158 and others.